New batches of a specialised blood product will arrive in New Zealand hospitals on Saturday after a contamination scare in Australia.
Routine maintenance at the CSL Biotherapies plant in Melbourne, which produces the blood product known as albumin, found traces of a coolant in some batches.
The blood is used in intensive care and surgery in New Zealand and Australian hospitals.
New Zealand's Ministry of Health says testing has suggested the contamination of the product is limited to batches produced between December 2011 and January this year.
Hospitals are using stocks produced before that period and there have been no reports of patients suffering ill-effects from any contamination, it says.